Roche Expands Digital Pathology Open Environment to Advance AI-Driven Cancer Diagnostics
2 Sources
2 Sources
[1]
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment By Investing.com
, /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY (OTC:RHHBY)) announced today the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology. The seamless integration is facilitated through Roche's navify Digital Pathology enterprise software, an application for the pathologist's workflow, which now incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments. "We are excited to welcome these new collaborators into our digital pathology ecosystem," said , Head of Pathology Lab for Roche Diagnostics. "By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide." The collaborators are: With these new collaborations and integrations, Roche emphasises its commitment to improving patient outcomes and advancing personalised healthcare by providing scientists and clinicians with the resources they need to deliver precise and effective cancer diagnoses. About Roche Digital Pathology As the leading provider of pathology lab solutions, Roche delivers an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated AI-based clinical image analysis algorithms. Roche minimises variables that can impact analysis, and it is this end-to-end development that produces the quality results healthcare providers and researchers can depend on. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented AI tools into routine clinical practice and is committed to investing in and shaping the future of pathology. The Roche Digital Pathology Open Environment serves as a collaborative platform that brings together innovative AI-based pathology tools. About Roche Founded in 1896 in , as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. All trademarks used or mentioned in this release are protected by law. Some algorithms are Research Use Only and not for use in diagnostic procedures. Please consult with local markets on the regulatory status of these algorithms.
[2]
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment - Roche Holding (OTC:RHHBY)
The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare. Roche is now integrating more than 20 artificial intelligence (AI) algorithms from eight new collaborators into its digital pathology open environment. AI technology helps enhance pathology with high value insights, which can benefit cancer patients through precision medicine leading to targeted treatment. TUCSON, Ariz., Sept. 9, 2024 /PRNewswire/ -- Roche (RO ROG,RHHBY announced today the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology. The seamless integration is facilitated through Roche's navify® Digital Pathology enterprise software, an application for the pathologist's workflow, which now incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments. "We are excited to welcome these new collaborators into our digital pathology ecosystem," said Jill German, Head of Pathology Lab for Roche Diagnostics. "By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide." The collaborators are: Deep Bio: Algorithm for prostate cancer detection, grading, and tumour quantificationDiaDeep: Algorithms for breast cancer biomarker quantificationLunit: Tumour proportion score (TPS) analysis for non-small cell lung cancerMindpeak: Algorithms for breast biomarkers and pan tumour PD-L1 for lung, gastric, esophageal, bladder and breast cancersOwkin: Algorithm for the screening of microsatellite stability in colorectal cancerQritive: Algorithms for screening and grading of prostate cancer, analysing lymph nodes for metastasis, and screening for colon cancerSonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancerStratipath: Algorithm for risk profiling of invasive breast cancer With these new collaborations and integrations, Roche emphasises its commitment to improving patient outcomes and advancing personalised healthcare by providing scientists and clinicians with the resources they need to deliver precise and effective cancer diagnoses. About Roche Digital Pathology As the leading provider of pathology lab solutions, Roche delivers an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated AI-based clinical image analysis algorithms. Roche minimises variables that can impact analysis, and it is this end-to-end development that produces the quality results healthcare providers and researchers can depend on. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented AI tools into routine clinical practice and is committed to investing in and shaping the future of pathology. The Roche Digital Pathology Open Environment* serves as a collaborative platform that brings together innovative AI-based pathology tools. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. * Some algorithms are Research Use Only and not for use in diagnostic procedures. Please consult with local markets on the regulatory status of these algorithms. Roche Media Relations Jo Lynn Garing, +1 317-363-7286 or [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-advances-ai-driven-cancer-diagnostics-by-expanding-its-digital-pathology-open-environment-302241196.html SOURCE Roche Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Roche has announced the expansion of its Digital Pathology Open Environment, integrating AI-powered tools from third-party developers to enhance cancer diagnostics and improve patient care.
Roche's Digital Pathology Innovation
Roche, a global pioneer in pharmaceuticals and diagnostics, has taken a significant step forward in the field of cancer diagnostics by expanding its Digital Pathology Open Environment. This initiative aims to integrate artificial intelligence (AI) powered tools from various third-party developers, potentially revolutionizing the way cancer is diagnosed and treated
1
.Enhancing Diagnostic Accuracy and Efficiency
The expanded open environment allows pathologists to access a wider range of AI-powered image analysis tools directly within Roche's uPath enterprise software. This integration is designed to streamline workflows and enhance the accuracy of cancer diagnosis. By leveraging AI algorithms, pathologists can potentially identify subtle patterns and features in tissue samples that might be challenging to detect through traditional methods
2
.Collaboration with Third-Party Developers
Roche's initiative involves collaboration with several third-party developers, including Ibex Medical Analytics, Mindpeak, and Nucleai. These partnerships bring specialized AI tools to the platform, each focusing on different aspects of cancer diagnostics. For instance, Ibex's Galen Breast and Prostate solutions aid in detecting and grading cancer in breast and prostate biopsies, while Mindpeak's BreastIHC offers automated quantification of breast cancer biomarkers
1
.Impact on Patient Care
The integration of these AI tools is expected to have a significant impact on patient care. By improving the speed and accuracy of cancer diagnosis, patients may receive more timely and appropriate treatment. Additionally, the standardization of diagnostic processes through AI assistance could lead to more consistent results across different healthcare settings
2
.Future Prospects and Challenges
While the expansion of Roche's Digital Pathology Open Environment represents a major advancement, it also raises questions about the future of pathology. As AI becomes more integrated into diagnostic processes, there will likely be a need for pathologists to adapt their skills and workflows. Additionally, ensuring the reliability and validation of AI algorithms in clinical settings will be crucial for widespread adoption
1
2
.Related Stories
Regulatory Considerations
As with any medical technology, regulatory approval and compliance are critical. Roche emphasizes that their digital pathology solution, including the NAVIFY Digital Pathology software, is CE-IVDR and FDA-cleared. However, the integration of third-party AI tools may require additional regulatory scrutiny to ensure safety and efficacy in clinical practice
2
.Broader Implications for Healthcare
This development by Roche is part of a larger trend towards digitalization and AI integration in healthcare. It reflects the growing importance of interdisciplinary approaches, combining expertise in medicine, computer science, and data analysis. As these technologies evolve, they have the potential to not only improve cancer diagnostics but also to transform other areas of healthcare, potentially leading to more personalized and effective treatment strategies
1
2
.References
Summarized by
Navi
[1]
Related Stories
Roche and Qritive Partner to Revolutionize Global Cancer Diagnostics with AI
12 Sept 2024
Precision for Medicine and SOPHiA GENETICS Partner to Enhance AI-Driven Biomarker Discovery and Clinical Trials
08 Apr 2025•Health
Mayo Clinic Launches Digital Pathology Platform to Revolutionize Healthcare with AI
14 Jan 2025•Health
Weekly Highlights
1
Anthropic Secures $13B in Funding, Reaching $183B Valuation Amid AI Industry Boom
Business and Economy
2
OpenAI Partners with Broadcom to Develop Custom AI Chips, Challenging Nvidia's Dominance
Technology
3
Tesla Proposes $1 Trillion Pay Package for Elon Musk, Tied to Ambitious AI and Robotics Goals
Business and Economy
Weekly Highlights
Explore today's top stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
